Skip to main content

Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma.

Publication ,  Journal Article
Almeida-Filho, P; Ravizzini, GC; Almeida, C; Borges-Neto, S
Published in: Clin Nucl Med
June 2000

PURPOSE: This study evaluated the potential of Tc-99m sestamibi whole-body scan (WBMIBI) as an alternative to whole-body I-131 scan (WBI) for the follow-up of patients with differentiated thyroid carcinoma. MATERIALS AND METHODS: We evaluated 99 consecutive patients with differentiated thyroid carcinoma who had total or nearly total thyroidectomy followed by an ablative dose of I-131 (86 women, 13 men; mean age, 44 +/- 12 years). WBMIBI was performed and serum thyroglobulin (TG) levels were obtained at least 6 months after I-131 treatment. All persons were receiving levothyroxine therapy. RESULTS: From the total of 110 studies performed, WBMIBI and TG were in agreement in 96% and discordant in 4%. From the 27 crossed studies (WBMIBI x TG) with at least one abnormal result, 16 were compared with WBI. In four cases, the WBI did not reveal functioning thyroid tissue when both TG and WBMIBI indicated tumoral activity. In one case of pulmonary metastasis confirmed by chest radiographs, with a normal TG value, the results of both WBMIBI and WBI were positive. CONCLUSIONS: WBMIBI should be considered as a scintigraphic method in the follow-up of differentiated thyroid carcinoma. This technique can show the sites of tumoral activity with optimal image resolution, particularly in those with abnormal TG and negative WBI results, and it is a potentially valuable tool in patients with anti-TG antibodies. The WBI in patients having ablation should be reserved only for therapy planning.

Duke Scholars

Published In

Clin Nucl Med

DOI

ISSN

0363-9762

Publication Date

June 2000

Volume

25

Issue

6

Start / End Page

443 / 446

Location

United States

Related Subject Headings

  • Whole-Body Irradiation
  • Thyroxine
  • Thyroidectomy
  • Thyroid Neoplasms
  • Thyroglobulin
  • Technetium Tc 99m Sestamibi
  • Radiopharmaceuticals
  • Radionuclide Imaging
  • Nuclear Medicine & Medical Imaging
  • Neoplasm Recurrence, Local
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Almeida-Filho, P., Ravizzini, G. C., Almeida, C., & Borges-Neto, S. (2000). Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma. Clin Nucl Med, 25(6), 443–446. https://doi.org/10.1097/00003072-200006000-00011
Almeida-Filho, P., G. C. Ravizzini, C. Almeida, and S. Borges-Neto. “Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma.Clin Nucl Med 25, no. 6 (June 2000): 443–46. https://doi.org/10.1097/00003072-200006000-00011.
Almeida-Filho P, Ravizzini GC, Almeida C, Borges-Neto S. Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma. Clin Nucl Med. 2000 Jun;25(6):443–6.
Almeida-Filho, P., et al. “Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma.Clin Nucl Med, vol. 25, no. 6, June 2000, pp. 443–46. Pubmed, doi:10.1097/00003072-200006000-00011.
Almeida-Filho P, Ravizzini GC, Almeida C, Borges-Neto S. Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma. Clin Nucl Med. 2000 Jun;25(6):443–446.

Published In

Clin Nucl Med

DOI

ISSN

0363-9762

Publication Date

June 2000

Volume

25

Issue

6

Start / End Page

443 / 446

Location

United States

Related Subject Headings

  • Whole-Body Irradiation
  • Thyroxine
  • Thyroidectomy
  • Thyroid Neoplasms
  • Thyroglobulin
  • Technetium Tc 99m Sestamibi
  • Radiopharmaceuticals
  • Radionuclide Imaging
  • Nuclear Medicine & Medical Imaging
  • Neoplasm Recurrence, Local